dr. cheng on phase iii findings of lenvatinib in hcc
Published 7 years ago • 248 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
1:24
phase iii findings for lenvatinib in hcc
-
1:50
dr. cheng on the need for biomarkers in hcc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
8:55
implication of upfront lenvatinib in hcc
-
2:31
dr. bruix on the phase iii resorce trial in hcc
-
6:54
upfront lenvatinib in unresectable hcc
-
4:54
reflect trial: frontline lenvatinib’s value in hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
2:20
dr. bruix discusses the updated findings of the resorce trial in hcc
-
6:51
hcc: use of lenvatinib and sorafenib
-
1:15
dr. huey on the importance of patient selection in hcc
-
7:24
practical considerations for using lenvatinib in hcc
-
2:07
dr. wirth discusses the safety profile of lenvatinib as seen in the select trial
-
2:59
dr. cheng on tumor heterogeneity in hcc and challenges for clinical trials
-
1:52
dr. bekaii-saab discusses the fda approval of lenvatinib in hcc
-
3:35
emerging multikinase inhibitors in hcc
-
1:28
dr. wirth on the use of lenvatinib in hypertensive patients with thyroid cancer